The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism

Insel Gruppe AG, University Hospital Bern90 enrolled

Overview

Despite the strong association of hyperparathyroidism with arachidonic acid related lipid signals, little research has been performed over the years. A better understanding of the link between arachidonic acid remodeling, prostaglandin and endocannabinoid production with primary hyperparathyroidism in primary tissue/cells might open up new avenues for biomarker and thus to a potential therapeutic target. Arachidonic acid remodeling might also have an impact on depression and elevated cytokines in patients with primary hyperparathyroidism. The investigators therefore will assess the correlation between postoperative improvement of PHQ-9 and cytokine levels with arachidonic acid remodeling.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Primary Hyperparathyroidism

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Primary hyperparathyroidism with planned surgery * Written informed consent Exclusion Criteria: * Age \<18 years * Secondary/tertiary hyperparathyroidism * Renal insufficiency * Participant is pregnant * Participant is incapable of giving an informed consent

Locations (1)

Department of visceral surgery and transplant surgery, Berne University Hospital

Bern, Switzerland

Outcomes

Primary Outcomes

Activity-based protein profiling (ABPP) will be used to assess the enzymes involved in calcium induced stress signals and endocannabinoid activation

Time frame: 2 months

Secondary Outcomes

Measurement of the level of parathyroid hormone

Time frame: 2 months

Measurement of the level of calcium

Time frame: 2 months

Measurement of the level of cortisol

Time frame: 2 months

Measurement of the level of 25-hydroxyvitamin D

Time frame: 2 months

Measurement of the levels of the enzymes involved in the endocannabinoid system activation (diacylglycerol lipase; monoacylglycerol lipase, phospholipases, cyclooxygenases)

Time frame: 2 months

Measurement of the level of endocannabinoids, arachidonic acid species, prostanoids and related anti-inflammatory lipids

Time frame: 2 months

Measurement of the level of IL-6 and TNF-α

Time frame: 2 months

Assessment of Patient Health Questionnaire - 9

The Patient Health Questionnaire (PHQ-9) is described as a valid depression scale with good sensitivity and specificity for detecting depressive disorders, ranging from 1 to 27. Depression severity: 1 to 4: minimal; 5 to 9: mild; 10 to 14: moderate; 15 to 19: moderately severe; 20 to 27: severe

Time frame: 2 months